7RUN

Crystal structure of phosphorylated RET tyrosine kinase domain complexed with a pyrrolo[2,3-d]pyrimidine inhibitor.

Summary for 7RUN

• Entry DOI: 10.2210/pdb7run/pdb
• Descriptor: Proto-oncogene tyrosine-protein kinase receptor Ret, CHLORIDE ION, 1-(4-{(1s,3s)-3-[4-amino-5-(3-amino-4-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclobutyl}piperazin-1-yl)ethan-1-one (3 entities in total)
• Functional Keywords: tyrosine-protein kinase, inhibitor, cell adhesion, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 2
• Total formula weight: 78276.55

Authors

Lee, C.C.,Spraggon, G. (deposition date: 2021-08-17, release date: 2022-01-19, Last modification date: 2024-11-06)

Primary citation

Mathison, C.J.N.,Yang, Y.,Nelson, J.,Huang, Z.,Jiang, J.,Chianelli, D.,Rucker, P.V.,Roland, J.,Xie, Y.F.,Epple, R.,Bursulaya, B.,Lee, C.,Gao, M.Y.,Shaffer, J.,Briones, S.,Sarkisova, Y.,Galkin, A.,Li, L.,Li, N.,Li, C.,Hua, S.,Kasibhatla, S.,Kinyamu-Akunda, J.,Kikkawa, R.,Molteni, V.,Tellew, J.E.
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3- d ]pyrimidine RET Inhibitors.
Acs Med.Chem.Lett., 12:1912-1919, 2021

PubMed Abstract: The selective inhibition of RET kinase as a treatment for relevant cancer types including lung adenocarcinoma has garnered considerable interest in recent years and prompted a variety of efforts toward the discovery of small-molecule therapeutics. Hits uncovered via the analysis of archival kinase data ultimately led to the identification of a promising pyrrolo[2,3-]pyrimidine scaffold. The optimization of this pyrrolo[2,3-]pyrimidine core resulted in compound , which demonstrated potent RET kinase inhibition and robust efficacy in RET-driven tumor xenografts upon multiday dosing in mice. The administration of was well-tolerated at established efficacious doses (10 and 30 mg/kg, po, qd), and plasma exposure levels indicated a minimal risk of KDR or hERG inhibition , as evaluated by Miles assay and free plasma concentrations, respectively.

PubMed: 34917254
DOI: 10.1021/acsmedchemlett.1c00450

Experimental method

X-RAY DIFFRACTION (3.51 Å)